RNAZ TransCode Therapeutics

Who are they?

TransCode's team combines decades of oncology drug discovery and development expertise, life science business acumen and Wall Street knowledge to add both scientific insight and valuable strategic perspective to address cancer and create a sustainable commercialization product pipeline. Our scientists have decades of experience in the foundational areas of RNA and drug development, employing antisense oligonucleotide, or ASO, and silencing RNA approaches.

Stock Information

6,250,000 shares of its common stock at a public offering price of $4.00 per share

The Company intends to use the proceeds for testing required to file an IND for the Phase 0 trial of TTX-MC138, for further development of TTX-MC138, strategic expansion of their drug candidate portfolio, and the balance for working capital and general corporate purpose.

Recent 13G filed by AIGH Capital Management, LLC for 1,270,500 shares.

What is their pipeline?

• TTX-MC138 focuses on treatment of Metastatic cancer (90% of cancer deaths)
• TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas
• TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively
• Potential utility of biomarker test for microRNA-10b

Optimized TTX Platform advantages

• Properties allow for quantitative non-invasive imaging via MRI & measurement of drug bioavailability during treatment
• Allows for target engagement and avoids early clearance by the liver and kidneys
• Low toxicity potential; low immunogenicity potential and highly stable
• Strong binding affinity and specificity to intended target
• Similar constructs have proven to be clinically safe

Technicals

• More time needed to analyze this one. But for now keep watching the OVERSOLD indicators. 4$ IPO, so anything under that is a good load zone at this point.
  

References

https://vimeo.com/295266648

After four weeks of therapy, mice treated with TTX-MC138 showed complete regression of lymph node metastases. By contrast, in the control groups, there was metastatic progression (Within-Subjects ANOVA: p < 0.05). Treatment was discontinued once complete metastatic regression was observed. By the end of the study at 12 weeks, no recurrence of disease was observed and there was complete regression without recurrence in 100% of treated subjects having this cancer model.